Evidence map›Paper›PMID 28086917›Full record

Trial reportJournal of neuroinflammation2017

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Charbel Moussa, Michaeline Hebron, Xu Huang, Jaeil Ahn, Robert A Rissman, Paul S Aisen, R Scott Turner

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neuroinflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01504854 (Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease), which is not on this map. Cited by 332 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 7 pooled it
30.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01504854 phase2completednot on this map

Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease

TypeinterventionalSponsorAlzheimer's Disease Cooperative Study (ADCS)Ran2012 to 2014Enrolled119ConditionsAlzheimer's DiseaseArmsResveratrol, Placebo
3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 7 syntheses or guidelines pooled it, 679 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Investigation of the impact of resveratrol on sublethal-dose ALA-PDT in glioblastoma cells.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  20. Article

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Charbel MoussaDepartment of Neurology, Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, National Parkinson's Foundation Center of Excellence, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC, 20057, USA. cem46@georgetown.edu.ORCID 0000-0002-2012-7063
Michaeline HebronDepartment of Neurology, Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, National Parkinson's Foundation Center of Excellence, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC, 20057, USA.
Xu HuangDepartment of Neurology, Laboratory for Dementia and Parkinsonism, Translational Neurotherapeutics Program, National Parkinson's Foundation Center of Excellence, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC, 20057, USA.
Jaeil AhnDepartment of Neurology, Memory Disorders Program, Translational Neurotherapeutics Program, Georgetown University, Washington DC, USA.
Robert A RissmanDepartment of Biostatistics, Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington DC, 20057, USA.
Paul S AisenAlzheimer's Therapeutic Research Institute (ATRI), University of Southern California, San Diego, CA, USA.
R Scott TurnerAlzheimer's Disease Cooperative Study (ADCS), Department of Neurosciences, University of California, La Jolla, San Diego, CA, USA.
Georgetown University · USAlzheimer’s Disease Neuroimaging Initiative · USUniversity of Southern California · US

Funding

TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
NIA NIH HHS U01 AG010483
6 · The paper itself

Abstract

backgroundTreatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF Aβ40 levels and activities of daily living (ADL) scores.

methodsFor this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF Aβ42 <600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated). We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases (MMPs) in parallel in CSF and plasma samples.

resultsCompared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF Aβ42 levels during the 52-week trial, but did not alter tau levels.

conclusionsCollectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.

trial registrationClinicalTrials.gov NCT01504854.

Indexed as

Activities of Daily LivingAdaptive ImmunityAlzheimer DiseaseAmyloid beta-PeptidesAnti-Inflammatory Agents, Non-SteroidalChemokine CCL5Cognition DisordersCytokinesDouble-Blind MethodEncephalitisFemaleFibroblast Growth Factor 2Follow-Up StudiesHumansMaleMatrix Metalloproteinase 9Amyloid beta-Peptidesamyloid beta-protein (1-42)Anti-Inflammatory Agents, Non-SteroidalChemokine CCL5CytokinesFibroblast Growth Factor 2Matrix Metalloproteinase 9Peptide FragmentsResveratrolStilbenestau ProteinsAlzheimerInterleukin-4Macrophage-derived chemokine (MDC)Matrix metalloproteinase-(MMP)-9Resveratrol

Identifiers

PMID28086917
PMCPMC5234138
OpenAlexW2574949547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.